Últimas noticias sobre CEL-SCI (AMEX:CVM) Bolsa

CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Equities

Offerings

Small Cap

Acciones de Cel-Sci Corporation (CVM) caen tras anunciar oferta pública

Advanced Environmental Recycling Technologies

AERT

AILE

CTXR

HONE

HSON

INTZ

KORE

LITM

NATR

PDYN

REKR

SLDP

VINC

WATT

Descubre los mayores ganadores y perdedores en el mercado previo tras movimientos impactantes en acciones clave hoy.

Las acciones de Vincerx Pharma (VINC) suben alrededor del 64%; 20 acciones que se mueven en premercado

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

Biotech

General

CEL-SCI Met With Saudi Food And Drug Authority, Says Is Preparing To Submit A Regulatory Filing For The Approval Of Multikine As A Neoadjuvant Treatment Of Newly Diagnosed Previously Untreated Locally Advanced Head And Neck Cancer

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

APDN

BFRG

IMAB

IRWD

MTSR

RSLS

STSS

THRD

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares rose 86.6% to $9.52 during Friday's regular session. The market value of their outstanding shares is at $15.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock moved upwards by 85.15% to $2.37. The company's market cap stands at $5.0 million. </li>
<li>CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares rose 35.78% to $15.14. The company's market cap stands at $543.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 35.02% to $38.13. The company's market cap stands at $496.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 34.42% to $0.02. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 27.88% to $0.27. The company's market cap stands at $22.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 53.3% to $2.31 during Friday's regular session. The company's market cap stands at $5.6 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.04% to $0.24. The market value of their outstanding shares is at $6.1 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares declined by 29.45% to $2.76. The market value of their outstanding shares is at $143.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock fell 22.96% to $1.68. The market value of their outstanding shares is at $3.0 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock declined by 21.52% to $0.22. The company's market cap stands at $1.3 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares declined by 15.96% to $0.48. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBLL

LUCY

MSPR

ONVO

PRTG

YCBD

12 Health Care Stocks Moving In Friday's Intraday Session

Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival
A third-party head and neck cancer study published in "Cancer Cell" confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54235406&amp;newsitemid=20250408565129&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=8529d78500a48ee3a0fee230cd3462e9">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies" by Li Housaiyin et. al., <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1535610825000789%3Fvia%253Dihub&amp;esheet=54235406&amp;newsitemid=20250408565129&amp;lan=en-US&amp;anchor=Cancer+Cell&amp;index=2&amp;md5=a6109e5ec0a40224cd7c3f761761be2b">Cancer Cell</a> (2025) provides support for CEL-SCI's approach aimed at seeking early regulatory approval for Multikine&#x2A; (Leukocyte Interleukin, Injection) as a neoadjuvant in the treatment of newly diagnosed previously untreated locally advanced head and neck cancer based on early tumor responses.
The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The study in Cancer Cell, which had 41 evaluable patients, gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer.

CEL-SCI Announces Study Published In 'Cancer Cell' Confirms Pre-Surgical Tumor Response In Head And Neck Cancer Patients Treated With Its  Multikine Improves Overall Survival, Supporting Early Regulatory Approval As A Neoadjuvant Treatment For Locally Advanced Head And Neck Cancer

CEL-SCI Announces Publication From Prior 3 Study Of Multikine In Journal 'Pathology and Oncology Research'

Shares of Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial results and <a href="https://www.benzinga.com/quote/HROW/earnings">issued 2025 revenue guidance</a>.
Harrow shares jumped 23.1% to $28.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 45.7% to $26.96 in pre-market trading after jumping over 46% on Monday.</li>
<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) rose 30.4% to $0.7985 in pre-market trading. Bon Natural Life shares dipped 57% on Monday after the company announced the pricing of a $12 million offering of 8,333,332 shares at $1.44/share.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) gained 19.2% to $0.4774 in pre-market trading following a 10% surge on Monday.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) gained 17.8% to $1.39 in pre-market trading after jumping 7% on Monday.</li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) gained 15% to $1.46 in pre-market after gaining 4% on Monday.</li>
<li>Key Tronic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) gained 14.2% to $3.05 in pre-market trading.</li>
<li>FinVolution Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) rose 11% to $10.12 following fourth-quarter results.</li>
<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) rose 9.3% to $14.10 in pre-market trading after gaining 3% on Monday.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 6.3% to $4.73 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 40.3% to $0.5250 in pre-market trading.</li>
<li>Bakkt Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) fell 29.4% to $9.05 in pre-market trading after gaining 7% on Monday.</li>
<li>Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) dipped 25.8% to $0.95 in pre-market trading following fourth-quarter results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) declined 24.3% to $0.1280 in pre-market trading.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) fell 24.1% to $0.0802 in pre-market trading after dipping over 6% on Monday.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares tumbled 18.5% to $1.31 in pre-market trading. AirNet Technology shares jumped 98% on Monday after the company announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 13.1% to $0.2469 in pre-market trading. CEL-SCI announced the pricing of $2.56 million best-efforts offering of 16 million shares of common stock.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell 6.8% to $10.70 in today's pre-market trading following a fourth-quarter sales miss.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) fell 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket

CEL-SCI Announces Pricing Of $2.56M Best-Efforts Offering Of 16M Shares Of Common Stock

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares increased by 107.6% to $5.19 during Monday's pre-market session. The company's market cap stands at $7.3 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 39.89% to $1.08. The company's market cap stands at $1.0 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares rose 19.85% to $1.63. The company's market cap stands at $258.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares moved upwards by 19.23% to $3.1. The company's market cap stands at $340.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares increased by 17.47% to $4.1. The market value of their outstanding shares is at $19.8 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 14.63% to $0.35. The market value of their outstanding shares is at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares decreased by 25.0% to $2.55 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock decreased by 22.29% to $0.55. The market value of their outstanding shares is at $41.1 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) shares fell 14.9% to $57.75. The market value of their outstanding shares is at $11.1 billion. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 12.55% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) shares declined by 11.65% to $9.71. The company's market cap stands at $425.0 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined by 9.46% to $0.34. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ANNX

CAPS

CNTX

INCY

MAZE

PALI

REVB

SHPH

SNTI

12 Health Care Stocks Moving In Monday's Pre-Market Session

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo&#xAE;) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1
Multikine&#x2A; is uniquely positioned in the field as the only oncology drug used as a neoadjuvant that has demonstrated overall survival benefit in head and neck cancer patients whose tumors express low levels of PD-L1
Multikine aims to address a major treatment gap for head and neck cancer patients where about 70% have low PD-L1 expression, in its upcoming confirmatory Registration Trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54223970&amp;newsitemid=20250314970798&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=0ce157001ccda3a5a8e3d1caba8cd8a9">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced that a third-party study published on March 6, 2025 in JAMA Oncology titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial" provided data that support Multikine's use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression in its upcoming confirmatory head and neck cancer Registration Trial.

CEL-SCI Announces That A Third-Party Study Published In Jama Oncology Titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-stratified Chemoradiation Therapy In HPV-Negative Head And Neck Cancer: The DEPEND Phase 2 Non-Randomized Clinical Trial" Provided Data That Support Multikine's Use As A Neoadjuvant Treatment In Patients With Tumors Having Low PD-L1

Cel-Sci shares are trading higher after the company announced it is in the final stages of its 212-patient confirmatory registration study of Multikine.

CEL-SCI Announces Final Stages For 212-Patient Confirmatory Registration Study Of Multikine In Advanced Head And Neck Cancer To Confirm Phase 3 Efficacy And Safety Results

CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments.
"CEL-SCI is very uniquely positioned at this moment as an immuno-oncology company with a vast amount of data from the largest Phase 3 head and neck cancer study ever performed, with statistically significant evidence that our drug can successfully fight cancer and extend lives in head and neck cancer," stated CEL-SCI CEO, Geert Kersten. "We hope to deliver a new standard of care to patients while substantially transforming our company's valuation to reflect what we believe to be the intrinsic value of our cancer drug. The statistical analysis shows that our very soon to be initiated small confirmatory Registration Study has a very high chance of success and we will have indications of efficacy as early as 2026. Should the pre-surgical tumor responses mirror what we saw in the Phase 3 data, we believe we will be on the path for accelerated and/or conditional approval for Multikine next year."

CEL-SCI Highlights Multikine's 73% 5-Year Survival Benefit In Low PD-L1 Head And Neck Cancer Patients; New Phase 3 Confirmatory Trial Planned With Ergomed As CRO Partner; Accelerated Approval Possible In 2026 Based On Tumor Response Data

CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.75 percent increase over losses of $(0.16) per share from the same period last year.

Earnings

Earnings Beats

CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.2% to $2.71 during Monday's pre-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock moved upwards by 57.47% to $0.31. The market value of their outstanding shares is at $10.2 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 42.43% to $0.53. The company's market cap stands at $29.1 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares rose 39.39% to $4.6. The market value of their outstanding shares is at $8.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 17.64% to $1.8. The company's market cap stands at $7.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 15.29% to $0.63. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares declined by 40.0% to $8.06 during Monday's pre-market session. The company's market cap stands at $24.3 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock decreased by 29.97% to $0.42. The company's market cap stands at $26.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 13.64% to $0.38. The company's market cap stands at $27.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 12.48% to $3.93. The company's market cap stands at $203.6 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock fell 10.66% to $0.53. The company's market cap stands at $314.9 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock declined by 9.91% to $0.19. The market value of their outstanding shares is at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CPHI

MRNS

OTRK

PLRZ

QNRX

SENS

TRAW

XAIR

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.7% on Monday.
The Dow traded down 0.67% to 42,702.02 while the NASDAQ fell 0.73% to 19,578.50. The S&amp;P 500 also fell, dropping, 0.72% to 5,928.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares rose by 0.2% on Monday.
In trading on Monday, consumer discretionary shares dipped by 1.2%.
Top Headline
U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 5% to $6.69. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 12% to $9.27. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 7% to $14.48. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertical Aerospace Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares dropped 15% to $13.20. The company recently announced it has finalized an investment agreement for up to $50 million in new funding.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 41% to $7.92. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 31% to $0.42. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded down 0.6% at $2,616.00.
Silver traded down 2% to $29.385 on Monday, while copper fell 0.8% to $4.0880.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.46%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.57%. Spain's IBEX 35 Index rose 0.05%, while London's FTSE 100 fell 0.35%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
<li>The Dallas Fed&#8217;s Texas manufacturing activity index rose six points to a reading of 3.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CTKB

EVTL

HSAI

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 100 points on Monday.
The Dow traded down 0.61% to 42,725.52 while the NASDAQ fell 0.58% to 19,608.47. The S&amp;P 500 also fell, dropping, 0.59% to 5,935.35.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.6% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.2%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 6% to $6.79. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 13% to $9.36. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 9% to $14.69. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares dropped 20% to $56.60.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.25. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 28% to $0.4301. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.32 while gold traded down 0.6% at $2,615.80.
Silver traded down 1.5% to $29.505 on Monday, while copper fell 0.7% to $4.0930.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index rose 0.01%, while London's FTSE 100 fell 0.62%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

QMCO

Crude Oil Gains 1%; Chicago PMI Falls In December

WIIM

Cel-Sci shares are trading lower after the company announced a $5 million public offering of 16.13 million shares.

U.S. stocks traded lower this morning, with the Dow Jones dipping around 600 points on Monday.
Following the market opening Monday, the Dow traded down 1.40% to 42,390.68 while the NASDAQ fell 1.53% to 19,419.90. The S&amp;P 500 also fell, dropping, 1.43% to 5,885.51.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.3% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.1%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Intrusion Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares shot up 192% to $6.34.</li>
<li>Shares of Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>)got a boost, surging 210% to $0.7556.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares were also up, gaining 186% to $1.1600.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares dropped 40% to $2.71.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.15. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 35% to $0.3923. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $71.24 while gold traded down 0.4% at $2,622.40.
Silver traded down 1% to $29.680 on Monday, while copper fell 0.6% to $4.0985.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX fell 0.4% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.6%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

US Stocks Open Lower; Dow Tumbles 600 Points

Cel-Sci Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares are trading lower premarket on Monday.
On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42716897/cel-sci-announces-pricing-of-5-million-public-offering" rel="noreferrer noopener">warrants at $0.31 per share</a>.
The company aims to raise around $5 million in gross proceeds. The offering is expected to close on December 31, 2024, subject to customary conditions.
The company plans to use proceeds to support the development of Multikine, general <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42711737/cel-sci-announces-proposed-public-offering-of-common-stock" rel="noreferrer noopener">corporate purposes, and working capital</a>.
Earlier this month, CEL-SCI emphasized the strong biological rationale for using Multikine in its FDA-approved confirmatory registration study for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42461679/cel-sci-highlights-biological-rationale-for-the-use-of-multikine-in-the-confirmatory-registration-" rel="noreferrer noopener">head and neck cancer</a>.
The study, involving 212 newly diagnosed patients with locally advanced, resectable head and neck cancer, will focus on those who demonstrated a 73% survival rate with Multikine compared to 45% for control patients in the prior Phase 3 trial.
Price Action: CVM shares are down 29.9% at $0.4204 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42719119/us-stock-futures-slip-after-fridays-fall-santa-rally-in-doubt-analyst-calls-it-a-bit-of-profit-taking" target="_blank" rel="noreferrer noopener">US Stock Futures Slip After Friday&#8217;s Fall: &#8216;Santa Rally&#8217; In Doubt? Analyst Calls It A Bit Of Profit-Taking</a></li>
</ul>
Photo via Shutterstock.

What's Going On With Cel-Sci Shares Premarket On Monday?

U.S. stock futures declined on Monday after ending <a href="https://www.benzinga.com/24/12/42711387/wall-streets-santa-rally-at-risk-palantir-dethrones-nvidia-consumer-confidence-pulls-back-this-week-in-the-markets">lower </a>on Friday. All four index futures slipped in trade.
Although ‘Santa Rally' has not picked up pace despite rising over 1% on Christmas Eve, the S&amp;P 500 index is on its way to registering a robust 20% plus return for the second consecutive year in 2024.
The 10-year and two-year Treasury notes yielded 4.59% and 4.30%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025, FOMC meeting was at 88.8%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.18%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.21%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.21%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.02%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.23% to $593.66 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.20% to $521.43, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stock markets experienced a <a href="https://www.benzinga.com/news/earnings/24/12/42717902/dow-dips-over-300-points-but-records-weekly-gain-greed-index-remains-in-fear-zone">lower</a> close on Friday as major indices retreated following gains on a weekly basis. The Dow Jones Industrial Average declined by over 300 points, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) suffered losses.
The Dow Jones Industrial Average closed at 42,992.21, down approximately 0.77%, whereas, the S&amp;P 500 and Nasdaq Composite also experienced declines, falling by 1.11% and 1.49%, respectively.
All sectors within the S&amp;P 500 ended the day in negative territory. Consumer discretionary, communication services, and information technology sectors recorded the most significant losses.
On the economic front, U.S. wholesale inventories decreased by 0.2% in November. The U.S. trade deficit in goods widened to $102.86 billion.
Despite Friday&#8217;s losses, major indices still recorded positive returns for the week. The Dow Jones gained approximately 0.4%, ending a three-week losing streak. The S&amp;P 500 added 0.7%, and the Nasdaq rose by about 0.8%.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.49%</td>
<td>19,722.03</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.11%</td>
<td>5.970.84</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.77%</td>
<td>42,992.21</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.56%</td>
<td>2,244.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Chamath Palihapitiya, the billionaire investor, and former Facebook executive, explained in an X post that greater concentration in a few stocks increases the risks of investing.
He highlighted the inequality in the weight of the stocks within the S&amp;P 500 index and said, "If there is any market volatility, the lack of diversification could cause massive impairment."
Kevin Gordon, the director and senior investment strategist at Charles Schwab shared a graphic showing the top ten stocks in the S&amp;P 500 represent 40% of the index market capitalization.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This needs to be fixed or it will end in disaster. Why? Average Americans buy S&amp;P 500 index ETFs, in part, because Buffett told them to. They were told they would pay very little and get diversification in the 500 best companies on earth to ride out storms. But as… <a href="https://t.co/YEYhjvrSg7">https://t.co/YEYhjvrSg7</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1873144394100187263?ref_src=twsrc%5Etfw">December 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As the ‘Magnificent Seven&#8217; stock led the market lower on Friday, Louis Navellier of Navellier &amp; Associates in his note said, "The Santa Claus rally is in serious doubt now." But he quipped that "It certainly appears to be a bit of profit-taking."
Reinstalling confidence among investors Navellier added that Friday's selloff should not be worrisome and the ‘B team' of traders were getting rid of their inventory before the weekend.
"Investors shouldn&#8217;t worry about the sell-off – it&#8217;s just what we call inventory cleaning. But there is a sell-off today, and if you did want to buy, it's not a bad time to nibble. Normally, we rally going into New Year&#8217;s, and we normally rally in the new year. So, if we don&#8217;t, it means we have to wait until the A team comes back, which will of course be after the New Year&#8217;s holiday," he added.
The 10-year Treasury yield hit 4.631% during Friday's session, which was its highest level since May 30, 2024. However, it is currently yielding 4.59% on Monday.
Talking about the spiking yields, Ed Yardeni, the president at Yardeni Research said in a note "The Bond Vigilantes are sending a loud warning message. They aren&#8217;t convinced Donald Trump, the new sheriff coming to town, will maintain fiscal law and order any better than the old sheriff. They are also losing their confidence in Jerome Powell, the deputy in charge of monetary law and order."
According to Navellier, "The bond vigilantes have been pushing the narrative that the Trump tariffs are going to be inflationary, but the reality is that a strong U.S. dollar causes the prices of commodities and imported goods to decline."
Yardeni, in his note, mentioned that a pullback in the markets may have already started. "We still think that the 10-year yield should trade around 4.50% plus/minus 25bps in 2025. But we can&#8217;t rule out a move back up to last year&#8217;s high of 5.00% early next year. That&#8217;s another reason why we expect a stock market pullback/correction that might have started already. The S&amp;P 500 peaked at a record 6090.27 on Dec. 6," he said.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
A few important data points will be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Monday, Chicago Business Barometer (PMI) data for December will announced at 9:45 a.m., ET.</li>
</ul>
<ul>
<li>November's pending home sales data will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Tuesday, November's S&amp;P Case-Shiller home price index for 20 cities will be announced at 9:00 a.m., ET.</li>
</ul>
<ul>
<li>No data is slated to be released on Wednesday, Jan. 1, owning to a New Year's holiday.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Dec. 28 will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Construction spending data for November will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, ISM manufacturing data for December will be announced at 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down 43.34% in premarket trade after it priced its $5 million public offering of 16.13 million common shares at 31 cents per share.</li>
</ul>
<ul>
<li>CCSC Technology International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) was up 31.71% after its earnings on Friday. Its revenue surged by 22.9% year-over-year to $9.2 million for the third quarter.</li>
</ul>
<ul>
<li>Citius Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) was down 16.58% after reporting a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share.</li>
</ul>
<ul>
<li>Genius Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) was up 15.81% in premarket after posting first-half revenue of $4.9 million, down from $11.8 million in the year-ago period. Its net assets surged 177% to $54.6 million from $19.7 million as of Dec. 31, 2023.</li>
</ul>
<ul>
<li>Intrusion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) was up 125.93% in premarket after Dow Newswire reported Streeterville Capital has acquired a 9.8% stake in the company.</li>
</ul>
<ul>
<li>Amplitech Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) was up 24.17% as it raised $5.8 million in gross proceeds for the company before fees and expenses were deducted. It was a direct offer of 1,871,000 shares of common stock at $3.10 per share to institutional investors.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.18% to hover around $70.47 per barrel.
The gold spot index was down by 0.25% to $2,625.56 per ounce. The Dollar Index was down 0.05% to 107.947 level.
Asian markets were mostly lower on Monday as Hong Kong&#8217;s Hang Seng, Japan&#8217;s Nikkei 225, Australia&#8217;s ASX 200, and South Korea&#8217;s Kospi declined. Whereas, China&#8217;s CSI 300 ended higher. European markets were mixed.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678368/sp-500-hits-57-all-time-highs-in-record-breaking-2024-magnificent-7-drive-30-of-nasdaqs-surge">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq&#8217;s Surge</a> </li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Futures

Economics

AMPG

CCTG

NVDA

TSLA

US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking

Press Releases

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Opinion

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Comments

CEL-SCI

Noticias

Últimas noticias sobre CEL-SCI (AMEX:CVM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL